Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-mat...

Full description

Saved in:
Bibliographic Details
Main Authors: Shigeru Yutani, Kazuomi Ueshima, Kazumichi Abe, Atsushi Ishiguro, Junichi Eguchi, Satoko Matsueda, Nobukazu Komatsu, Shigeki Shichijo, Akira Yamada, Kyogo Itoh, Tetsuro Sasada, Masatoshi Kudo, Masanori Noguchi
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2015/473909
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items